Supernus Pharma (SUPN) Misses Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Supernus Announces First Quarter 2023 Financial Results
May 9, 2023 4:05 PM EDTFirst quarter 2023 total revenues of $153.8 million, compared to $152.5 million in first quarter 2022 Qelbree® net product sales of $25.8 million, compared to $8.3 million in first quarter 2022GOCOVRI® net product sales of $26.0 million, compared to $22.6 million in first quarter 2022Excluding net product sales of Trokendi XR® in both periods, total net product sales increased 25% First quarter 2023 GAAP operating earnings of $5.2 million, compared to $2.0 million in first quarter 2022First quarter 2023 non-GAAP operating earnings of $30.5 million, compared to $28.0... More
